Navigation Links
Wyeth's Torisel and Roche/Genentech's Avastin Will Challenge Pfizer's Sutent to Become the Clinical Gold Standard for Treatment of Metastatic Renal Cell Carcinoma

Increased Survival Rates and Decreased Disease Progression Rates Are the

Advantages, According to a New Report from Decision Resources

WALTHAM, Mass., Aug. 7 /PRNewswire/ -- Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that Wyeth's Torisel and Roche/Genentech's Avastin will challenge Pfizer's Sutent as the clinical gold standard for the treatment of metastatic renal cell carcinoma. According to the new report entitled Two Hot New Drugs Battle for Top Position: A Renal Cell Carcinoma Study, both Torisel and Avastin offer increased overall survival rates as well as decreased disease progression times.

"Metastatic renal cell carcinoma is an end-stage disease in which the primary goal of treatment is to prolong survival," said Mohamed Muhsin, analyst at Decision Resources. "Phase III clinical trials have shown Torisel to increase the median overall survival rates of patients by 49 percent. High rates of partial response and stable disease, extended median time to progression, and overall survival rates for patients on Torisel are promising. Phase II trials for Avastin have shown that 61% of patients had stable disease. The median progression-free survival rate was eleven months, and the one-year progression-free survival rates for patients with objective response, minor response, and stable disease were 80%, 57% and 27%, respectively."

About Two Hot New Drugs Battle for Top Position: A Renal Cell Carcinoma Study

Two Hot New Drugs Battle for Top Position: A Renal Cell Carcinoma Study covers the current and future state of the metastatic renal cell carcinoma drug market. The report includes the following:

-- More than 3,000 physician responses that define drug attributes that

drive prescription now and in the future.

* Clinical end point tradeoffs that are most influential to


* Areas of unmet need with highest potential.

* Benchmark trial results for specific drug opportunities.

* Patient share potential for emerging therapies and target product


-- Decision Resources proprietary analysis of commercial factors that

accelerate or constrain a drug's market potential.

* Promotion: DTC spend, detailing intensity.

* Reimbursement: formulary tier, prior approval restriction, quantity


* Labeling: black box warnings, approved patient segments,


* Competition: order of entry, pricing, generic entry, pipeline sales


* Medical practice: decision trees, treating physician type, line of


-- Comparisons of the key clinical attributes of current and emerging

therapies in the areas of efficacy, safety, and delivery.

-- Analysis and supporting data that identifies the clinical "Gold

Standard" now and over the next ten years.

-- Key insights as to which clinical end points have the greatest

influence on physician decision-making.

The report can be purchased by contacting Decision Resources. Members of the media may request an interview with an analyst.

About Decision Resources

Decision Resources, Inc., ( is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Elizabeth Marshall

Decision Resources, Inc.


SOURCE Decision Resources, Inc.

Copyright©2007 PR Newswire.

Related medicine technology :

1. Biotheras Imprime PGG Enhanced Effectiveness of Avastin in Cancer Study
2. FDA MedWatch: Avastin (bevacizumab) and Formation of Tracheoesophageal Fistula in a Recent Clinical Study in Patients with Limited-stage Small Cell Lung Cancer
3. Data Presented at AACR Meeting Shows Peregrines Selective Anti-VEGF Antibodies are as Effective as Avastin(R) in Preclinical Cancer Models
4. Neuroblastoma Expert Reviews Progress and Challenges in Fighting Difficult Pediatric Cancer
5. Novavax Pandemic Flu Vaccine Provided Protection Against a Lethal Challenge of Live Virus, Pre-Clinical Data Show
6. Annual Meeting of the Consortium of Multiple Sclerosis Centers Focuses on the Challenges of Care and Research in Multiple Sclerosis
7. Independent Publication Confirms Growing Therapeutic Challenge of T315I Mutation in Patients with CML, Notes ChemGenex
8. Independent Publication Confirms Growing Therapeutic Challenge of T315I Mutation in Patients with CML, Notes ChemGenex
9. Novavax Reports Positive Pre-Clinical Study Results from Live Virus Challenge to Pandemic Flu Vaccine
10. LigoCyte Pharmaceuticals Presents Data Showing Heterosubtypic Protection Against Influenza Challenge With Virus-Like Particle Immunization
11. Schering-Plough Addresses Major Milestones and Challenges in Treatment of Patients With Chronic Hepatitis C
Post Your Comments:
(Date:11/25/2015)... 2015 Research and Markets ( ) ... - Global Forecast to 2020" report to their ... for 37.21% of the total market share in 2014. ... region is projected to growth at the highest CAGR ... primarily to the fast growing water, industrial gas treatment, ...
(Date:11/24/2015)... 25, 2015 WuXi PharmaTech (Cayman) Inc. ("WuXi" ... open-access R&D capability and technology platform company serving the ... China and the ... extraordinary general meeting of shareholders held today, the Company,s ... and approve the previously announced agreement and plan of ...
(Date:11/24/2015)... N.C. , Nov. 24, 2015  In the ... projects in an effort to quickly uncover new insights, ... --> --> However, ... a market research project and ensure that all rules ... and industry standards. Another major barrier to efficiently launching ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... , ... Beddit® has launched a new Android app for use ... a more intuitive SleepScore™ that rates sleep quality on a 100-point scale and makes ... by a proprietary algorithm. Beddit analyzes the data to provide an easy to understand ...
(Date:11/25/2015)... , ... November 25, 2015 , ... ... provide scholarships for people struggling with eating disorders as a result of the ... second annual event, held at Fox Run Golf Club in Eureka, will help ...
(Date:11/25/2015)... ... 2015 , ... Many people know of the common symptoms of low thyroid ... skin. But many people who find their cholesterol levels and weight are creeping up ... especially if they don’t have any of the other symptoms. , Thyroid hormone plays ...
(Date:11/24/2015)... ... 2015 , ... Genesis Chiropractic Software helps practice owners automate ... between the practice owner and the patient that automatically manages all five aspects ... Click here to learn more. , According to Dr. Brian ...
(Date:11/24/2015)... Dallas, Texas (PRWEB) , ... November 24, 2015 , ... ... of all charitable donations are made in the last five weeks of the year ... #GivingTuesday was created in 2012 to connect the nation’s charities with those individuals who ...
Breaking Medicine News(10 mins):